Yahoo Finance28 天
DURYSTA’s Market Potential Across the 7MM is Set to Soar During the Study Period (2020 ...
AbbVie’s DURYSTA (bimatoprost SR) Overview DURYSTA (bimatoprost intracameral implant) is a prescription treatment designed to lower intraocular pressure (IOP) in individuals with open-angle ...
Medscape8 年
Effect of Switching From Latanoprost to Bimatoprost in POAG
Purpose: We investigated the intraocular pressure (IOP) variations after switching from 0.005% latanoprost to 0.01% bimatoprost in open-angle glaucoma patients who experienced IOP elevation during ...